FOR IMMEDIATE RELEASE
MEDIA CONTACT: Sawyer Lipari
Lambert & Co.
OmniSeq Names Dr. Shengle Zhang as New Lab Director
Fast-growing cancer diagnostic laboratory continues focus on development of innovative product breakthroughs
(BUFFALO, N.Y. – March 10, 2020) Today OmniSeq®, a leading molecular diagnostic company, named medical industry veteran Shengle Zhang, M.D., M.S. as its new laboratory director and molecular pathologist. The hire is the latest in a series of strategic moves by OmniSeq as it continues to develop tools to help oncologists determine precision medicine for their patients.
Dr. Zhang’s addition follows LabCorp’s second investment in OmniSeq in 2019 and the extension of its exclusive distribution agreement with the molecular diagnostics company. OmniSeq has had double-digit growth in both annual revenue and sales volume since 2017. Additionally, the company added 14 personnel to its team since mid-2019, with its workforce of clinical laboratory and research scientists, technology and business professionals numbering more than 55 today.
OmniSeq, a CAP-accredited, molecular diagnostics lab headquartered in Buffalo, New York, develops and performs genomic and immune profiling tests that analyze biomarkers associated with response to cancer drugs in order to inform precision medicine options for patients with advanced cancers. These next generation sequencing testing methodologies provide more precise guidance to oncologists and patients in the selection of the right therapy or clinical trial by delivering personalized results. In addition, OmniSeq’s testing gives hope to patients who have limited FDA-approved therapeutic options by providing clinical trials enrolling near the patient for which they may be eligible based on their genomic and immune profile.
“I am excited to join the OmniSeq team as there is so much opportunity on the horizon for this company and in the next generation sequencing test market,” said Dr. Zhang. “OmniSeq’s innovative products, research and established reputation represent a great platform for growth. I am eager to help the company accelerate its progress and deliver on its mission of helping oncologists deliver precision medicine to their cancer patients.”
Dr. Zhang, a board-certified molecular diagnostic and molecular genetic pathologist, has more than 30 years of proven experience in the molecular diagnostic oncology space, both as a practitioner and in the academic research space. As laboratory director at OmniSeq, he will direct OmniSeq’s clinical laboratory operations in its performance of OmniSeq’s genomic and immune profiling tests. Dr. Zhang will also participate in biomarker discovery and clinical trial projects as well as OmniSeq’s new clinical test development initiatives.
Dr. Zhang joins OmniSeq from SUNY Upstate Medical University in Syracuse, New York—the only academic medical center in Central New York. During his distinguished 15-year career there, he served as both assistant director of Upstate University Hospital’s molecular diagnostic laboratory, director of its anatomical pathology laboratory, a professor of pathology and a molecular and surgical pathologist. Dr. Zhang’s research has been published in several leading journals, including Science, Cancer Research, Diagnostic Molecular Pathology and Journal of Clinical Oncology. He holds memberships in the College of American Pathologists, US and Canadian Academy of Pathology and the Association for Molecular Pathology.
Dr. Zhang received his medical degree from Wannan Medical College in Wuhu, Anhui, China, and his Master of Science in Biochemistry at Shangdong Academy of Medical Sciences in Jinan, China. He completed his anatomical pathology and clinical pathology residency at Saint Barnabas Healthcare System in New Jersey, his oncology pathology fellowship at Roswell Park Comprehensive Cancer Center in New York and his molecular genetic pathology fellowship at John Hopkins Medical Institute in Maryland.
“Beyond his immense expertise in the molecular diagnostic space, Dr. Zhang brings a track record of driving outstanding results from the fast-moving markets we serve,” said Margot Schoenborn, CEO of OmniSeq. “OmniSeq is positioned for significant growth, and our team is working hard to ensure we have the right talent, partners and products to deliver unmatched value to these markets.”
OmniSeq, an innovation of Roswell Park Comprehensive Cancer Center, is a molecular diagnostic laboratory based in Buffalo, N.Y. OmniSeq endeavors to find the right drug or the right trial for every patient by improving access to better cancer treatment options through molecular profiling. OmniSeq offers three NGS-based assays: OmniSeq MSI NGS®, OmniSeq Advance®, and OmniSeq Comprehensive®. For more information about OmniSeq’s clinical products or pharmaceutical services, or to speak with a OmniSeq CARES® specialist, call +1-800-781-1259 or visit www.omniseq.com.